These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18420211)

  • 1. Do we need to consider inflammatory markers when we treat atherosclerotic disease?
    Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
    Atherosclerosis; 2008 Sep; 200(1):1-12. PubMed ID: 18420211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease and atherosclerosis.
    Gaudio E; Nobili V; Franchitto A; Onori P; Carpino G
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S297-305. PubMed ID: 23073871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
    Targher G; Arcaro G
    Atherosclerosis; 2007 Apr; 191(2):235-40. PubMed ID: 16970951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease.
    Michalsen A; Lehmann N; Pithan C; Knoblauch NT; Moebus S; Kannenberg F; Binder L; Budde T; Dobos GJ
    Eur J Clin Nutr; 2006 Apr; 60(4):478-85. PubMed ID: 16306923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome.
    Carbone F; Montecucco F; Mach F; Pontremoli R; Viazzi F
    Thromb Haemost; 2013 Nov; 110(5):940-58. PubMed ID: 23966104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of non-alcoholic fatty liver disease in cardiovascular disease.
    Perseghin G
    Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?
    Matusik P; Guzik B; Weber C; Guzik TJ
    Thromb Haemost; 2012 Sep; 108(3):443-56. PubMed ID: 22872109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
    Targher G
    Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pro-inflammatory and anti-inflammatory markers in coronary artery disease and acute ischemic coronary syndrome].
    Fragoso-Lona JM; Ramírez-Bello J; Cruz-Robles D; Pérez-Méndez O; de la Peña A; Vargas-Alarcón G
    Arch Cardiol Mex; 2009; 79(1):54-62. PubMed ID: 19545076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans.
    Liu SW; Qiao SB; Yuan JS; Liu DQ
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):202-7. PubMed ID: 19178507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome.
    Lucero D; Zago V; López GI; Graffigna M; Fainboim H; Miksztowicz V; Meroño T; Belli S; Levalle O; Wikinski R; Brites F; Berg G; Schreier L
    Clin Chim Acta; 2011 Jan; 412(1-2):143-7. PubMed ID: 20887718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and other agents for vascular inflammation.
    Owens CD
    J Vasc Surg; 2012 Dec; 56(6):1799-806. PubMed ID: 23017371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
    Haffner SM
    Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory markers and the metabolic syndrome.
    Athyros VG; Elisaf M; Mikhailidis DP
    Atherosclerosis; 2005 Nov; 183(1):187-8. PubMed ID: 16054632
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.